Borussertib, known as an irreversible allosteric inhibitor of the protein AKT, has demonstrated its ability to inhibit cell proliferation in preliminary studies involving colon and pancreatic cancers with KRAS mutations 11, 33. Here, KRAS is linked to pancreatic neoplasm.